<DOC>
	<DOCNO>NCT02577588</DOCNO>
	<brief_summary>The study `` Phase I trial Adoptive T cell Therapy Activated P53 specific T cell Treatment Advanced Colorectal Cancer '' open label , single arm trial .</brief_summary>
	<brief_title>Trial Adoptive T Cell Therapy With Activated P53 Specific T Cells Treatment Advanced Colorectal Cancer</brief_title>
	<detailed_description>Most patient colorectal carcinoma ( CRC ) accumulate high number endogenous tumor antigen specific cytotoxic helper memory T cell blood . Upon appropriate reactivation , tumor antigen specific T cell recognize eliminate autologous tumor cell . This achieve ex vivo stimulation antigen pulse autologous dendritic cell absence regulatory T cell . Upon adoptive transfer , specifically reactivate T cell cancer patient efficiently reject autologous human tumor vivo . A major target antigen anti tumor effector T cell CRC patient p53 , overexpressed many colorectal cancer . Within clinical trial , high number endogenous tumor specific T cell harvest leukapheresis blood CRC patient harbour p53-reactive T cell . Isolated T cell deplete regulatory T cell specifically reactivate three day ex vivo three synthetic long peptide contain immunogenic region p53 use autologous dendritic cell antigen present cell . Activated T cell re-infused patient . Ten patient CRC stage UICC IV routine first line FOLFOX 6/Bevacizumab therapy plan receive singular treatment autologous T cell product dose 5x10^7 ( first three six patient ) 5x10^8 ( last four seven patient ) cell . Patient treatment follow-up perform National Center Tumor Diseases ( NCT ) Department General , Visceral Transplantation Surgery , University Heidelberg . Leukapheresis take place DRK-Blutspendedienst Baden-Württemberg-Hessen Mannheim generation therapeutic cell perform GMP Unit Cellular Therapy DKFZ . Analysis blood sample respect special immune parameter carry Immune Monitoring Laboratory , Department Translational Immunology NCT , Heidelberg . The primary objective study evaluate safety tolerability adoptive transfer ex vivo reactivate p53 specific T cell obtain peripheral blood .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Histologically confirm UICC stage IV colorectal cancer non resectable primary tumor and/or metastases Previous palliative standard systemic treatment FOLFOX , FOLFIRI , FOLFIRINOX combination Bevacizumab Cetuximab/Panitumumab , currently respective treatment The following situation least four cycle FOLFOX , FOLFIRI , FOLFIRINOX combination Bevacizumab Cetuximab/Panitumumab apply : Disease control ( stable disease , partial response complete response ) accord routine imaging Resection tumor and/or metastasis still impossible Tolerability systemic treatment The decision treat physician continue standard background treatment Presence tumorreactive T cell blood detect ex vivo IFNγ EliSpot assay classification reaction response blood sample ECOGperformance status 0 1 Adequate vein status cubital fossas 16 G puncture ( white permanent venous catheter , Braunüle ; EN ISO 6009 ) Age ≥ 18 year , ethnic origin gender Ability patient understand character individual consequence clinical trial Patients willing able comply schedule visit , treatment plan , laboratory test , study procedure Written inform consent ( must available enrolment trial ) Negative pregnancy test ( female childbearing potential ) Women childbearing potential male patient partner childbearing potential willing use adequate contraception ( failure rate le 1 % per year use consistently correctly ) study three month last application T cell therapy At screen visit follow laboratory parameter apply within range specify : Lab Parameter Range WBC ≥4000/mm3 ( ≥4000/ul ) Platelets ≥80.000/mm3 ( ≥80.000/ul ) Creatinine ≤1.5mg/dl ALT , AST , total bilirubin &lt; 2.5 x ULN HB* &gt; 9 g/dl *HB control day 11 DRK Mannheim part procedures leukapheris . Exclusion Criteria Brain leptomeningeal metastasis , show MRI Scan Screening phase routinely available appropriate diagnostic ( CT , MRI , PET ) conduct within 3 month prior inclusion . Previous malignancy within past 5 year . However : Patients curatively treat basal cell carcinoma skin , early gastrointestinal cancer treat endoscopic resection and/or situ carcinoma cervix allow enrolment . History organ allograft prior hematopoetic stem cell transplantation History inflammatory bowel disease ( ulcerative colitis , Crohn 's disease ) History symptomatic autoimmune disease ( e.g. , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis [ e.g. , Wegener 's Granulomatosis ] ) History motor neuropathy consider autoimmune origin ( e.g. , GuillainBarré Syndrome ) Clinically significant cardiac disease ( NYHA Class III IV ) . Other serious illness , render patient unsuitable study entry multiple blood sample Serious intercurrent illness , require hospitalization HIV and/or HBC/HCV positivity , test appropriate infection diagnostics screen period Any active infection sign symptoms infection Patient pregnant breastfeed History hypersensitivity investigational medicinal product excipient present investigational medicinal product anticoagulance auxiliary medicianal product ( Heparin prophylaxis ) Treatment immunosuppressive drug ( e.g . systemic corticosteroid ) besides intermittent , antiemetic steroid application treatment FOLFOX , FOLFIRI , FOLFIRINOX combination Bevacizumab Cetuximab/Panitumumab . Topical inhalation steroid permit . Treatment approve anticancer therapy within 28 day prior enrolment , except background treatment FOLFOX , FOLFIRI , FOLFIRINOX combination Bevacizumab Cetuximab/Panitumumab.as recommend trial protocol Treatment live attenuate vaccine within 4 week first administration investigational medicinal product Treatment investigational agent participation another interventional clinical trial within 28 day prior enrolment . No patient allow enroll trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>p53 Antigen</keyword>
	<keyword>T cell therapy</keyword>
	<keyword>autologous</keyword>
	<keyword>Adoptive Cellular Immunotherapy</keyword>
</DOC>